Navigation Links
MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
Date:11/10/2011

DALLAS, November 10, 2011 /PRNewswire/ --

The report "Lung Cancer Drugs Market in G7 Countries (2005 - 2020) [ http://www.marketsandmarkets.com/Market-Reports/lung-cancer-drugs-market-508.html ]" analyzes and studies the major market drivers, restraints, and opportunities in North America, and Europe.

Browse in-depth TOC on Lung Cancer Drugs Market in G7 Countries (2005 - 2020).

Get Free 10% customization on reports
http://www.marketsandmarkets.com/Market-Reports/lung-cancer-drugs-market-508.html

Lung cancer is the most common form of cancer in terms of incidence and number of deaths. It is a disease wherein the cell lining of lung tissue grows uncontrollably and leads to the formation of tumor. There are two main types of lung cancer; small cell lung cancer that accounts for about 20% and non-small cell lung cancer (NSCLC) that accounts for about 80% of the total lung cancers.

The lung cancer drugs market was valued at around $4 billion in 2010 and is expected to reach about $13 billion by 2020, growing at a CAGR of 13.5% from 2015 to 2020. The market was dominated by drugs such as Avastin, Iressa, Gemzar, and Tarceva in 2010. However, by 2020, the market is expected to be dominated by talactoferrin (Agennix), an immunomodulatory drug; followed by Xalkori (Pfizer), and by ARQ 197 (ArQule/Daiichi Sankyo).

According to WHO, lung cancer prevalence is expected to grow in the emerging markets such as the BRIC countries and other Asian and African markets due to an increase in the use of tobacco products. Tobacco is the primary cause of around 80% of all lung cancers. The other causes such as radon gas exposure, asbestos can be causative factor for developing lung cancer.

The U.S. dominates the lung cancer drug market in North America with 93.5% share; whereas Germany dominates the market of Europe with 32.4% share.

Major players in the market include F. Hoffmann-La Roche Ltd (Switzerland), AstraZeneca Plc (U.K.), Eli Lilly and Company (U.S.), Sanofi-Aventis (France), Pfizer Inc. (U.S.), GlaxoSmithKline Pharmaceuticals Limited (U.K.), ArQule Inc. (U.S.), Daiichi Sankyo Co. Ltd. (Japan), Agennix AG (Germany), and Boehringer Ingelheim GmbH (Germany).

Other Reports by MarketsandMarkets

Upcoming Market Research by MarketsandMarkets

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical, pharmaceuticals market, semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our reports, please visit our website http://www.marketsandmarkets.com.

Contact:
Mr. Rohan
7557 Rambler Road,
Suite 727, Dallas, TX 75231
Tel: +1-888-6006-441
Email: sales@marketsandmarkets.com
MarketsandMarkets Blog @ http://www.marketsandmarketsblog.com/
http://twitter.com/marketsmarkets


'/>"/>
SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014
2. MarketsandMarkets: Global Biosimilars Product Market Worth $19.4 Billion by 2014
3. Marketsandmarkets: Global Minimally Invasive/ Non Invasive Market Worth $24.4 Billion by 2014
4. MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014
5. MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014
6. MarketsandMarkets: Global Bioinformatics Market Worth $8.3 billion by 2014
7. MarketsandMarkets: Global Biochip (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Market to Reach $5.6 Billion by 2015
8. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
9. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
10. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
11. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 23, 2017 , ... The Foundation ... unique partnerships, seeks outstanding early career nominees for the 2017 New Innovator in ... the needs of a world in which one in nine people suffers from ...
(Date:1/24/2017)... 2017 According to a new ... (Genetic, Cell-based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoiesis, Oncology, ... Biotech Companies, CRO) - Global Forecast to 2021", published ... Model Market for the forecast period of 2016 to ... Million by 2021 from USD 73.3 Million in 2016, ...
(Date:1/23/2017)... ... January 23, 2017 , ... USARAD Holdings Inc., a ... last year adding 65 new US and international facilities to its client base. ... well as one of US largest imaging center chains. USARAD continued its global ...
(Date:1/23/2017)... 2017 Atlas Genetics Ltd., the ultra-rapid ... Series D financing, raising $35 million from a syndicate including ... ... of the Atlas Genetics io® system has been completed with ... announced in February 2016.  This new Series D equity issue ...
Breaking Biology Technology:
(Date:1/11/2017)... Intoxalock, a leading ignition interlock provider, has ... patent-pending calibration device. With this new technology, Intoxalock is ... data logs and process repairs at service center locations, ... drunk driving through the application of cutting-edge technologies is ... also for the customer who can get back on ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
(Date:1/6/2017)... NEWARK, Calif. , Jan. 5, 2017  Delta ... introduced its iris scanning technology for automotive at CES® ... GNTX ) to demonstrate the use of ... to identify and authenticate the driver in a car, ... automobiles during the driving experience. Delta ID ...
Breaking Biology News(10 mins):